等待開盤 10-31 09:30:00 美东时间
-0.310
-2.01%
今日重点评级关注:富国银行:维持Kyverna Therapeutics"超配"评级,目标价从24美元升至27美元;Chardan Capital:维持Oculis Holding"买入"评级,目标价从33美元升至51美元
10-09 10:51
BTIG analyst Janine Stichter reiterates J.Jill (NYSE:JILL) with a Buy and maintains $26 price target.
10-08 18:30
Designer Brands (NYSE:DBI) will release its quarterly earnings report on Tuesda...
09-08 23:02
今日重点评级关注:Canaccord Genuity:维持Aris Mining"买入"评级,目标价从16.5美元升至17美元;花旗:维持Docusign"买入"评级,目标价从110美元升至115美元
09-05 09:40
J.Jill, Inc. (($JILL)) has held its Q2 earnings call. Read on for the main high...
09-05 08:03
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据J.Jill (JILL)的业绩会实录,我总结如下:</p> <p>• 财务业绩: - 总营收约1.54亿美元 - 毛利润约1.05亿美元 - 调整后EBITDA为2560万美元 - 调整后每股摊薄收益为0.81美元 - 自由现金流1700万美元 - 季末现金余额4600万美元</p> <p>• 财务指标变化: - 总营收同比下降0.8% - 可比销售同比下降1% - 毛利率为68.4%,同比下降约210个基点 - 毛利润同比下降约400万美元 - 调整后EBITDA同比下降,从3020万美元降至2560万美元 - 调整后
09-04 12:03
今日重点评级关注:花旗:维持Ionis Pharmaceuticals"买入"评级,目标价从69美元升至84美元;Melius Research:上调康明斯评级至"买入",目标价500美元
09-04 09:49
Ratings for J.Jill (NYSE:JILL) were provided by 5 analysts in the past three mo...
09-04 04:01
Telsey Advisory Group analyst Dana Telsey maintains J.Jill (NYSE:JILL) with a Market Perform and maintains $17 price target.
09-03 22:31
J. Jill shares are trading lower. The company announced Q2 financial results
09-03 21:18